Introduction {#s1}
============

The sphingolipid metabolic pathway is a fundamental feature of all eukaryotic cells ([@bib29]). It is required to produce complex sphingolipids, such as sphingomyelin and the expansive glycosphingolipid family, that are plasma-membrane building blocks. It also generates bioactive metabolites (such as ceramide, sphingosine, and sphingosine-1-phosphate) that alter cell activities, including growth regulation and apoptosis, through interactions with receptors and enzymes. Some segments of the pathway have been specialized in a cell- and tissue-specific manner to supply essential sphingolipids that have unique properties needed for key physiological functions (e.g., the production and transport of ultra-long chain ceramides for creating the skin permeability barrier, or specific glycosphingolipids for forming the tightly packed myelin membrane that insulates neuronal axons) ([@bib13]).

The de novo sphingolipid biosynthetic pathway begins with the condensation of an amino acid (usually serine) and a fatty acyl-CoA (usually palmitoyl-CoA) by the serine palmitoyltransferase (SPT) enzyme complex ([Figure 1A](#fig1){ref-type="fig"}) ([@bib29]). The first product, 3-keto-dihydrosphingosine, is then reduced to form dihydrosphingosine, which is subsequently acylated with fatty acids of different chain lengths to produce dihydroceramide. Introduction of a double bond into the sphingoid base generates ceramide, a central metabolic intermediate in the pathway. Ceramide, and its degradation product sphingosine, are bioactive and can cause cell death at elevated levels ([@bib20]). Complex sphingolipids -- sphingomyelin and glycosphingolipids -- are generated by addition of hydrophilic head groups to the ceramide anchor.

![*Ormdl3*, but not *Ormdl1* or *Ormdl2,* single knockout (KO) mice exhibit significantly increased levels of sphingolipids in the brain.\
(**A**) Schematic of the de novo sphingolipid biosynthetic pathway and its feedback inhibition by ORMDLs through the sensing of ceramide levels. SPT, serine palmitoyltransferase; 3KDHSph, 3-keto-dihydrosphingosine; DHSph, dihydrosphingosine; DHCer, dihydroceramide; Cer, ceramide; Sph, sphingosine; S1P, sphingosine-1-phosphate. (**B--D**) Generation of *Ormdl* KO mice. Panels show the intron-exon organizations of the *Ormdl* genes and the protein coding regions (white). (**B, C**) *Ormdl1* and *Ormdl2* KO mice were produced by CRISPR/Cas9-induced mutations, resulting in frameshifts and premature stop codons. The locations of sgRNA sequences (red), PAM sites (green), as well as the changes in DNA and protein are indicated. The base insertion in the CRISPR/Cas9 modified *Ormdl2* gene is underlined. (**D**) *Ormdl3* KO mice were generated by germline Cre-LoxP recombination to excise exons 2, 3, and part of exon 4, resulting in the deletion of the entire protein-coding sequence. (**E**) RT-qPCR of *Ormdl* WT RNA in brain of *Ormdl* KO mice relative to that in WT mice. The mice were 8 weeks old. Probes detect the WT *Ormdl* sequences. Data are expressed as means ± SD. Unpaired Student's *t* test; \*\*\*p\<0.001. nd, not detectable. n = 4 for all genotypes. (**F**) Levels of dihydrosphingosine, total dihydroceramide, total ceramide, and sphingosine were determined by HPLC-tandem MS on lipid extracts of whole brains harvested from 8-week-old WT, *Ormdl1* KO, *Ormdl2* KO, *Ormdl3* KO, *Ormdl1/2* double KO, *Ormdl1/3* double KO, and *Ormdl2/3* double KO mice ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Data are expressed as means ± SD. One-way ANOVA with Bonferroni correction; \*p\<0.05, \*\*\*p\<0.001. n = 8 for all genotypes. DKO, double knockout.\
Figure 1---source data 1.Levels of dihydrosphingosine, total dihydroceramide, total ceramide, and sphingosine from brains of WT, *Ormdl1* KO, *Ormdl2* KO, *Ormdl3* KO, *Ormdl1/2* double KO, *Ormdl1/3* double KO, and *Ormdl2/3* double KO mice.](elife-51067-fig1){#fig1}

Like sterols and glycerolipids, cellular sphingolipid levels are tightly regulated ([@bib7]; [@bib8]; [@bib21]). The discovery that the *Ormdl* gene family mediates feedback inhibition of de novo sphingolipid synthesis has provided insight into a homeostatic mechanism that controls sphingolipid generation in mammals ([@bib6]; [@bib11]). Three mammalian *Ormdl* genes exist (*Ormdl1*, *Ormdl2,* and *Ormdl3*), and they encode small transmembrane endoplasmic reticulum proteins with amino-acid identities of around 80% ([@bib23]). The ORMDL proteins, in complex with SPT, have the capacity to sense elevated ceramide levels and to inhibit SPT enzymatic activity, thereby blocking entry of de novo synthesized sphingolipid substrate into the sphingolipid biosynthetic pathway ([@bib11]; [@bib19]; [@bib33]) ([Figure 1A](#fig1){ref-type="fig"}).

The physiological contexts in which the ORMDLs are required are not well understood, but could inform us about when and why the de novo sphingolipid biosynthetic pathway requires negative regulatory control. Here, we investigated this issue by establishing knockout (KO) mice for each of the *Ormdl* genes. While the single KO mice were without overt phenotypes, we found that *Ormdl1/3* double KO mice exhibited a conspicuous phenotype, with elevated levels of sphingolipid metabolites, severe myelination defects and neurologic abnormalities. The results indicate that ORMDLs, functioning redundantly, are essential for maintaining control of the de novo sphingolipid biosynthetic pathway in a specific physiological context -- myelination -- where there is a high demand for sphingolipids.

Results {#s2}
=======

*Ormdl3*, but not *Ormdl1* or *Ormdl2*, single KO mice exhibit significantly increased levels of sphingolipids in brain {#s2-1}
-----------------------------------------------------------------------------------------------------------------------

In order to identify physiologic functions that are associated with the *Ormdl* genes, we established whole-body *Ormdl1* KO, *Ormdl2* KO, and *Ormdl3* KO mice ([Figure 1B--D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). *Ormdl1* and *Ormdl2* KOs were created by CRISPR/Cas9 genome editing in embryos ([@bib36]). In both cases, small deletions were introduced into exon 2, the first protein-coding exon of the two genes, to cause frameshifts in the coding sequences. These frameshifts produced premature terminations that eliminated more than 80% of the native protein-coding sequences ([Figure 1B and C](#fig1){ref-type="fig"}). For *Ormdl3,* gene targeting using homologous recombination at the *Ormdl3* locus in embryonic stem cells was applied. This introduced LoxP sequences flanking the region encompassed by *Ormdl3* exons 2 to 4, which contains the entire protein-coding region ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Mice carrying the floxed *Ormdl3* allele were bred with mice expressing Cre recombinase under the control of the ubiquitous EIIA promoter element ([@bib27]) to generate mice with a germline deletion of the entire *Ormdl3* protein-coding region (*Ormdl3* KO) ([Figure 1D](#fig1){ref-type="fig"}). For each of the single-gene KOs, mice carrying homozygous mutant alleles were obtained. RT-qPCR mRNA expression assays using brain RNA with probes corresponding to the deleted coding sequences indicated a deficiency of the individual wild-type (WT) *Ormdl* mRNA expression in the corresponding KO mouse, consistent with the introduced genomic changes ([Figure 1E](#fig1){ref-type="fig"}).

We measured levels of dihydrosphingosine and dihydroceramide, two intermediates generated early in the sphingolipid biosynthetic pathway exclusively through de novo synthesis, as well as levels of ceramide and sphingosine, two bioactive metabolites generated through both de novo synthesis and recycling ([@bib29]) ([Figure 1A](#fig1){ref-type="fig"}), in the brains of the *Ormdl1* KO, *Ormdl2* KO, and *Ormdl3* KO mice ([Figure 1F](#fig1){ref-type="fig"}). The *Ormdl1* KO and *Ormdl2* KO mice had levels of these four types of sphingolipids that were generally similar to those measured in WT mice; however, the *Ormdl3* KO mice had significantly elevated brain levels of each of these sphingolipids compared with WT mice. This result suggests that amongst the *Ormdl*s, *Ormdl3* has the greatest influence on the levels of these sphingolipids, including those generated solely through de novo synthesis, consistent with ORMDL inhibitory action on SPT ([Figure 1A](#fig1){ref-type="fig"}).

Elevated sphingolipids, neurologic phenotype and reduced viability when multiple *Ormdls* are deleted {#s2-2}
-----------------------------------------------------------------------------------------------------

*Ormdl1* KO, *Ormdl2* KO, and *Ormdl3* KO mice appeared overtly normal, with body weights not significantly different from those of WT mice at 8 weeks of age ([Figure 2A](#fig2){ref-type="fig"}). Intercross mating between respective single *Ormdl* KO mice produced litter sizes at weaning similar to those obtained through WT matings, suggesting normal fecundity and perinatal survival of *Ormdl1* KO, *Ormdl2* KO, and *Ormdl3* KO mice ([Figure 2B](#fig2){ref-type="fig"}).

![Elevated sphingolipids, neurologic phenotype and reduced viability when multiple *Ormdls* are deleted.\
(**A**) Body weight of 8-week-old male (n = 7--14) and female mice (n = 7--10) of the indicated genotypes. Each circle represents the weight of an individual mouse. Unpaired Student's *t* test; \*\*\*p\<0.001 versus WT mice. (**B**) Litter size was determined at weaning for offspring of the indicated matings. Each circle represents the number of weanlings from an individual litter (n = 19--25). bnd, breeding not done. One-way ANOVA with Bonferroni correction. (**C**) Image of an 8-week-old *Ormdl1/3* double KO mouse (right) showing characteristic clasping of the hindlimbs upon tail suspension, a sign of neurodegeneration. An *Ormdl1*^--/--^ *Ormdl3*^+/--^ littermate is shown (left). (**D**) Wire hang behavioral test. Eight-week-old mice were allowed to hang from a suspended wire using the forelimbs and the latency time to fall was recorded. The maximum hanging time was 180 s. Circles represent the mean of three determinations for each mouse (n = 16--29 mice for each genotype). One-way ANOVA with Bonferroni correction; \*\*\*p\<0.001 versus WT mice. DKO, double knockout.](elife-51067-fig2){#fig2}

To determine whether functional redundancy of the *Ormdl*s may have masked the expression of a phenotype in the single *Ormdl* KO mice, we cross-bred mice to produce *Ormdl* double KO mice in each of the three possible combinations -- *Ormdl1/2* double KO, *Ormdl1/3* double KO, and *Ormdl2/3* double KO mice -- and then characterized those offspring.

As with the *Ormdl* single KO mice, dihydrosphingosine, dihydroceramide, ceramide and sphingosine levels were measured in the brains of the *Ormdl* double KO mice ([Figure 1F](#fig1){ref-type="fig"}). Total amounts of these four sphingolipid groups were not increased above WT levels in *Ormdl1/2* double KO brain ([Figure 1F](#fig1){ref-type="fig"}). However, levels of dihydrosphingosine, dihydroceramide, ceramide and sphingosine in *Ormdl1/3* double KO brain substantially exceeded those of the *Ormdl3* single KO mice ([Figure 1F](#fig1){ref-type="fig"}). *Ormdl2/3* double KO brain dihydrosphingosine and dihydroceramide levels were significantly elevated above WT levels, but not to the extent observed in *Ormdl1/3* double KO mouse brain ([Figure 1F](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

At 8 weeks of age, *Ormdl1/2* and *Ormdl2/3* double KO males and females had body weights similar to those of WT mice ([Figure 2A](#fig2){ref-type="fig"}). However, both male and female *Ormdl1*/3 double KO mice weighed significantly less than WT mice. *Ormdl1/2* double KO and *Ormdl2/3* double KO mice were fertile and, when intercrossed, produced litter sizes similar to those of WT mating pairs ([Figure 2B](#fig2){ref-type="fig"}). Owing to their compromised physical and neurological status (below), breeding of *Ormdl1/3* double KO mice was not attempted.

The *Ormdl1*/*3* double KO mice exhibited abnormal hindlimb clasping upon tail suspension, a sign of possible neurodegeneration ([Figure 2C](#fig2){ref-type="fig"}) ([@bib28]). We used the forelimb wire hang behavioral test ([@bib1]), which measures strength and coordination, to assess the neuromuscular status of the single and double KO *Ormdl* mice at 8 weeks of age. The performance of *Ormdl1*, *Ormdl2*, and *Ormdl3* single KO mice and of *Ormdl1/2* and *Ormdl2/3* double KO mice was not significantly different from that observed for the WT mice ([Figure 2D](#fig2){ref-type="fig"}). However, the latency time to fall from the wire was significantly shorter for *Ormdl1/3* double KO mice than for WT mice, indicating that *Ormdl1/3* double KO mice had a behavioral deficit related to limb strength and coordination.

To determine the phenotypic consequences when more than one *Ormdl* gene was deleted, we crossed *Ormdl 1*^--/--^ *2* ^+/--^ *3* ^+/--^ mice and determined the genotype of the pups produced at weaning ([Table 1](#table1){ref-type="table"}). The expected distribution of genotypes of offspring from these mating pairs, based on Mendelian considerations, was significantly different from the genotype distribution actually obtained from the 156 offspring (p\<0.0001, Chi-square analysis). Notably, no triple *Ormdl1/2/3* KO mice were identified, although eight were predicted from the total number of offspring produced. Moreover, we also obtained much lower than predicted numbers of mice carrying only one WT *Ormdl* allele; that is, although 17 mice each were predicted for the *Ormdl 1*^--/--^* 2*^--/-- ^*3*^+/--^ and *Ormdl 1*^--/-- ^*2*^+/-- ^*3^--^*^/--^ genotypes, only 5 and 0, respectively, were actually obtained. The results suggest that the absence of all six WT *Ormdl* alleles causes either embryonic or neonatal lethality prior to weaning. Supporting this conclusion is the observation that inheritance of only one WT *Ormdl2* or *Ormdl3* allele substantially reduced viability.

###### Analysis of offspring from *Ormdl1*^--/--^ *Ormdl2*^+/--^ *Ormdl3*^+/--^ intercrosses.

Mouse genotypes were determined by PCR of tail-snip DNA of 156 pups at weaning from 38 litters derived from *Ormdl1*^--/--^* Ormdl2*^+/--^* Ormdl3*^+/--^ intercrosses. The genotype distribution frequency of offspring, predicted by Mendelian considerations and actually obtained, is shown. The Chi-square test was used to determine whether the obtained distribution of genotypes was statistically different from the predicted Mendelian ratios; p\<0.0001.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                 *Ormdl1^--/--\   *Ormdl1^--/--\   *Ormdl1^--/--\   *Ormdl1^--/--\   *Ormdl1^--/--\   *Ormdl1^--/--\   *Ormdl1^--/--\    *Ormdl1^--/--\    *Ormdl1^--/--\
                 ^Ormdl2^+/+^\    ^Ormdl2^+/+^\    ^Ormdl2^+/+^\    ^Ormdl2^+/--^\   ^Ormdl2^+/--^\   ^Ormdl2^+/--^\   ^Ormdl2^--/--^\   ^Ormdl2^--/--^\   ^Ormdl2^--/--^\
                 Ormdl3^+/--^*    Ormdl3^+/+^*     Ormdl3^--/--^*   Ormdl3^+/--^*    Ormdl3^+/+^*     Ormdl3^--/--^*   Ormdl3^+/+^*      Ormdl3^+/--^*     Ormdl3^--/--^*
  -------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------- ----------------- -----------------
  Observed \#    16               20               9                33               62               0                11                5                 0

  Observed %     10.26            12.82            5.77             21.15            39.74            0                7.05              3.21              0

  Predicted \#   9.75             19.5             9.75             19.5             39               19.5             9.75              19.5              9.75

  Predicted %    6.25             12.5             6.25             12.5             25               12.5             6.25              12.5              6.25
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Myelination is disrupted in *Ormdl1/3* double KO mice {#s2-3}
-----------------------------------------------------

Sphingolipids are major components of the lipid-rich myelin membrane that surrounds axons in the nervous system and are essential for proper myelin function ([@bib9]). We hypothesized that the ORMDLs may be especially critical when sphingolipid synthesis demand is high, such as during the formation of myelin membranes after birth. If de novo sphingolipid synthesis is poorly regulated under these circumstances by the absence of ORMDLs, increased amounts of sphingolipids might be generated, thereby interfering with orderly myelination in *Ormdl1/3* double KO mice. To evaluate the impacts of the ORMDLs on myelination, we examined sciatic nerves at 6 weeks of age in WT, *Ormdl1* KO, *Ormdl3* KO, and *Ormdl1/3* double KO mice by transmission electron microscopy (EM) ([Figure 3A](#fig3){ref-type="fig"}). *Ormdl1/3* double KO mouse sciatic nerve exhibited a highly abnormal morphology when compared with sciatic nerve obtained from WT or single *Ormdl1* and *Ormdl3* KO mice. The nerves from the *Ormdl1/3* double KO mice had a significantly lower frequency of myelinated axons per field compared with WT sciatic nerves ([Figure 3B](#fig3){ref-type="fig"}). No significant difference in the numbers of myelinated axons was observed between sciatic nerves from WT and *Ormdl1* or *Ormd3* single KO mice. A significantly higher frequency of redundant myelin, generally appearing as myelin 'outfoldings' ([@bib17]), was also observed in sciatic nerves from *Ormdl1/3* double KO mice compared with WT mice ([Figure 3C and D](#fig3){ref-type="fig"}).

![Myelination is disrupted in *Ormdl1/3* double KO mice.\
(**A**) Representative transmission EM images of sciatic nerve of 6-week-old WT, *Ormdl1* KO, *Ormdl3* KO, and *Ormdl1/3* double KO mice. Scale bars, 10 μm. (**B**) Axon density in sciatic nerve of 6-week-old WT, *Ormdl1* KO, *Ormdl3* KO, and *Ormdl1/3* double KO mice was determined by quantifying the number of myelinated axons in 7--12 EM fields per genotype. Data are expressed as means ± SD. One-way ANOVA with Bonferroni correction; \*\*\*p\<0.001. n = 3 for WT, n = 2 for *Ormdl1* KO, n = 2 for *Ormdl3* KO, n = 3 for *Ormdl1/3* double KO mice. (**C**) Example images of redundant myelin figures in sciatic nerve axons of 6-week-old *Ormdl1/3* double KO mice. Scale bars, 5 μm. (**D**) Percentage of myelinated axons in sciatic nerve of 6-week-old WT, *Ormdl1* KO, *Ormdl3* KO, and *Ormdl1/3* double KO mice showing redundant myelination was quantified in 7--12 EM fields per genotype. Data are expressed as means ± SD. One-way ANOVA with Bonferroni correction; \*\*\*p\<0.001. n = 3 for WT, n = 2 for *Ormdl1* KO, n = 2 for *Ormdl3* KO, n = 3 for *Ormdl1/3* double KO mice. (**E**) Levels of dihydrosphingosine, total dihydroceramide, total ceramide, sphingosine and hexosylceramide were determined by HPLC-tandem MS on lipid extracts of sciatic nerve from 8-week-old WT, *Ormdl1* KO, *Ormdl3* KO, and *Ormdl1/3* double KO mice ([Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Data are expressed as means ± SD. One-way ANOVA with Bonferroni correction; \*\*\*p\<0.001. n = 8 for all genotypes. DKO, double knockout.\
Figure 3---source data 1.Levels of dihydrosphingosine, total dihydroceramide, total ceramide, sphingosine and total hexosylceramide from sciatic nerves of WT, *Ormdl1* KO, *Ormdl3* KO, and *Ormdl1/3* double KO mice.](elife-51067-fig3){#fig3}

We measured levels of sphingolipid metabolites, dihydrosphingosine, dihydroceramide, ceramide, and sphingosine in sciatic nerves from these same genotypes. Sciatic nerve of *Ormdl1* KO mice had levels of these sphingolipids that were not significantly different from those from WT mice, whereas sciatic nerve of *Ormdl3* KO mice had significantly elevated levels of both dihydroceramide and ceramide compared with nerve from WT mice. However, the *Ormdl1/3* double KO sciatic nerve had significantly elevated levels of all four of these sphingolipid species compared with levels observed in the *Ormdl3* KO mice ([Figure 3E](#fig3){ref-type="fig"}).

We also measured sciatic nerve levels of hexosylceramide, comprising glucosyl and galactosylceramide, the major glycosphingolipids in myelin ([@bib37]). Hexosylceramide levels in the *Ormdl1* and *Ormdl3* single KO sciatic nerve were significantly increased compared to those in WT sciatic nerve ([Figure 3E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). However, sciatic nerve from *Ormdl1/3* double KO mice had decreased hexosylceramide levels, even though they had an 8-fold increase in the level of ceramide, the direct precursor for hexosylceramide synthesis. This result suggests that the large increase in precursor sphingolipid substrate ceramide may have saturated the terminal glycosylation step for hexosylceramide production.

Increased de novo sphingolipid biosynthesis in myelin-producing cells mimicked the phenotype of *Ormdl1/3* KO mice {#s2-4}
------------------------------------------------------------------------------------------------------------------

Our results are consistent with the conclusion that elevated sphingolipid synthesis resulting from *Ormdl1/3* deficiency causes dysmyelination and motor-function abnormalities in mice. Although reductions in the synthesis of specific sphingolipids have been associated with defects in myelination ([@bib9]), it has not been shown previously that increased de novo sphingolipid synthesis can cause myelination defects. To address this issue, we constructed a mouse model that allows for conditional expression of SPT activity ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). The transgenic mouse carries a single-chain version of the SPT enzyme with its three core subunits (SPTLC2, SPTSSA and SPTLC1) genetically fused (fusion\[f\]SPT) and under the control of a promoter that is activated by Cre recombinase expression (Stop-fSPT) ([@bib2]; [@bib15]). The Stop-fSPT cassette was introduced into the *Rosa26* locus using the phiC31 integrase system ([@bib35]).

In order to validate the model, we first generated mice carrying Stop-fSPT along with the *Mx1-Cre* gene, which can be activated by polyinosinic-polycytidylic acid (pIpC) administration to induce Cre expression in the liver ([@bib26]). After administration of pIpC, the fSPT polypeptide was detected by Western blotting, along with significantly increased SPT enzymatic activity, in Stop-fSPT/*Mx1-Cre* mouse liver compared with the liver of mouse controls carrying only Stop-fSPT ([Figure 4---figure supplement 1B and C](#fig4s1){ref-type="fig"}). Ceramide levels were significantly increased in the liver of mice expressing fSPT compared with that of control mice ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}).

Next, we specifically expressed the fSPT gene in cells that produce myelin in order to determine whether elevated sphingolipid synthesis causes dysmyelination, as was observed in the *Ormdl1/3* double KO mice. We generated mice carrying Stop-fSPT and the *Cre* gene under the control of the tamoxifen-inducible *Plp1* promoter ([@bib12]), which would allow for conditional fSPT expression in Schwann cells and oligodendrocytes upon *Cre* activation. *Cre* expression was induced at 4 weeks of age by use of a tamoxifen diet. After 2 weeks, the Stop-fSPT*/iPlp1-Cre* mice that had been fed the tamoxifen diet exhibited severe hindlimb paralysis ([Figure 4A](#fig4){ref-type="fig"}). Sciatic nerve expression of the fSPT protein was confirmed by Western blotting ([Figure 4B](#fig4){ref-type="fig"}). Transmission EM analysis of sciatic nerves from fSPT-overexpressing mice revealed reduced axon density ([Figure 4C and D](#fig4){ref-type="fig"}) and a significantly increased frequency of redundant myelin structures ([Figure 4E and F](#fig4){ref-type="fig"}), similar to those found in *Ormdl1/3* double KO mice ([Figure 3C and D](#fig3){ref-type="fig"}). Levels of dihydrosphingosine, total dihydroceramide, total ceramide, and sphingosine were significantly elevated in the sciatic nerves of the fSPT-expressing mice compared with those of control mice ([Figure 4G](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2A and B](#fig4s2){ref-type="fig"}). However, as in the *Ormdl1/3* double KO mice, hexosylceramide levels were decreased in sciatic nerves of fSPT-expressing mice even though these mice had highly elevated ceramide levels ([Figure 4G](#fig4){ref-type="fig"} -- [Figure 4---figure supplement 2C](#fig4s2){ref-type="fig"}).

![Increased de novo sphingolipid biosynthesis in myelin-producing cells mimicked the phenotype of *Ormdl1/3* KO mice.\
(**A**) Six-week-old fSPT*/iPlp1-Cre* (fSPT) mouse after treatment with tamoxifen for 2 weeks. (**B**) Western blot of fSPT expression in sciatic nerve of 6-week-old mice carrying Stop-fSPT without and with iPlp1*-Cre* (fSPT) after treatment with tamoxifen for 2 weeks. Bottom panel represents the same blot reprobed with an antibody against β-actin as a loading control. n = 3 for both genotypes. (**C**) Representative transmission EM images of sciatic nerve of 6-week-old Stop-fSPT and Stop-fSPT*/iPlp1-Cre* (fSPT)mice after treatment with tamoxifen for 2 weeks. Scale bars, 5 μm. (**D**) Axon density in sciatic nerve of 6-week-old Stop-fSPT and fSPT*/iPlp1-Cre* (fSPT) mice after treatment with tamoxifen for 2 weeks was determined by quantifying the number of myelinated axons in five and six EM fields for Stop-fSPT and fSPT*/iPlp1-Cre* mice (fSPT), respectively. Data are expressed as means ± SD. One-way ANOVA with Bonferroni correction; \*\*\*p\<0.001. n = 2 for both genotypes. (**E**) Example images of redundant myelin figures in sciatic nerve of 6-week-old fSPT*/iPlp1-Cre* (fSPT) mice after treatment with tamoxifen for 2 weeks. Scale bars, 2 μm. (**F**) Percentage of myelinated axons showing redundant myelination in sciatic nerve of 6-week-old Stop-fSPT and fSPT*/iPlp1-Cre* (fSPT) mice after treatment with tamoxifen for 2 weeks, quantified in five and six EM fields for Stop-fSPT and fSPT mice, respectively. Data are expressed as means ± SD. One-way ANOVA with Bonferroni correction; \*\*\*p\<0.001. n = 2 for both genotypes. (**G**) Levels of dihydrosphingosine, total dihydroceramide, total ceramide, sphingosine and hexosylceramide were determined by HPLC-tandem MS on lipid extracts of sciatic nerve from 6-week-old Stop-fSPT and fSPT*/iPlp1-Cre* (fSPT) mice after treatment with tamoxifen for 2 weeks ([Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). Data are expressed as means ± SD. One-way ANOVA with Bonferroni correction; *\**\*\*p\<0.001. n = 5 for Stop-fSPT, n = 7 for fSPT*/iPlp1-Cre* (fSPT) mice after treatment with tamoxifen for 2 weeks.\
Figure 4---source data 1.Levels of dihydrosphingosine, total dihydroceramide, total ceramide, sphingosine and hexosylceramide from sciatic nerves of mice carrying Stop-fSPT, without or with *iPlp1-Cre* (fSPT), after treatment with tamoxifen.](elife-51067-fig4){#fig4}

Discussion {#s3}
==========

The ORMDLs have been identified as regulators that mediate feedback inhibition of de novo sphingolipid synthesis to control sphingolipid levels ([@bib6]; [@bib11]; [@bib18]; [@bib39]). They are believed to act by sensing elevations in ceramide levels and by inhibiting SPT through direct protein--protein interactions within a multi-subunit enzyme complex ([@bib11]), although elevated free and phosphorylated sphingoid bases have also been suggested to inhibit SPT via ORMDLs ([@bib18]). The results presented here establish ORMDLs as functionally important modulators of in vivo sphingolipid levels in the nervous system. By evaluating mice in which either one or combinations of two of the three *Ormdl* genes were deleted, we found that mice lacking both *Ormdl1* and *Ormdl3* exhibit abnormal myelination in the sciatic nerve, as well as highly elevated sphingolipid levels in the nervous system. When de novo synthesis of sphingolipids was directly increased in myelin-producing cells by overexpression of fSPT, phenotypic manifestations similar to those seen in the *Ormdl1/3* double KO mice occurred. These findings indicate that ORMDLs suppress sphingolipid levels that, when elevated, cause dysmyelination.

After birth, during the acute phase of myelination, the Schwann cell membrane surface area expands several thousand times ([@bib38]). The myelin membrane is approximately 70--80% lipid by weight, with much of the non-sterol lipid made up of sphingolipids ([@bib37]). Thus, the formation of the myelin membrane requires an extremely high influx of new substrate through the sphingolipid biosynthetic pathway to produce the mature sphingolipids, largely galactosylceramide and sulfated galactosylceramide, that are needed for proper myelin formation ([@bib9]). Under conditions of very high sphingolipid synthesis, a lack of feedback inhibition could lead to high levels of ceramide if ceramide production exceeded the capacity of the downstream pathway to convert it into mature sphingolipids. Indeed, we found that the *Ormdl1/3* double KO mouse sciatic nerve contained high levels of ceramide together with lower levels of the mature sphingolipid hexosylceramide. The lower density of myelinated axons in the sciatic nerve of *Ormdl1/3* double KO mice may be a consequence of cell death due to this build-up of toxic sphingolipid precursor metabolites ([@bib20]; [@bib32]). Our findings are consistent with the idea that a key physiological function of the ORMDLs is to keep de novo sphingolipid synthesis in check so that ceramide production does not exceed the metabolic capacity of the cell to convert ceramide into mature, non-toxic sphingolipids that are destined for physiological processes ([@bib11]).

In this study, *Ormdl1/3* double KO mice exhibited a striking increase in the frequency of axons featuring redundant myelination. Redundant myelination, often observed as loops of myelin growing into the Schwann cell cytoplasm or surrounding the axon outside the normal myelin sheath, is believed to occur because of excessive myelin membrane growth or improper lipid composition ([@bib17]). Unbalanced sphingolipid synthesis, caused either by deletion of the *Ormdl*s in the *Ormdl1/3* double KO mice or by the overexpression of fSPT in myelin-producing cells, may have promoted the formation of myelin with abnormal lipid composition through the excessive production of sphingolipid precursors relative to mature sphingolipids. Incorrect sphingolipid composition, caused by a deficiency of galactosyceramide, has been shown to produce redundant myelin profiles ([@bib14]). Charcot-Marie-Tooth disease, an inherited demyelinating neuropathy, often features redundant myelination as its prominent histologic feature ([@bib10]; [@bib16]; [@bib17]). Interestingly, a distinct Charcot-Marie-Tooth phenotype in humans is caused by deficiency in the sphingolipid degradation enzyme, S1P lyase, a condition that can elevate ceramide levels ([@bib4]; [@bib31]).

When we attempted to generate *Ormdl* triple KO mice by crossing *Ormdl 1^--/-- ^2 ^+/-- ^3 ^+/--^* mice, no viable *Ormdl1/2/3* triple KO mice were identified at weaning. Further, the frequency of weaned pups with only one functional *Ormdl* allele produced from these crossings was much lower than that predicted from Mendelian considerations. These data suggest that the ORMDLs may also be needed for embryonic or neonatal viability. During embryonic growth, high levels of de novo sphingolipid synthesis would be required to support the extensive cellular proliferation that occurs ([@bib24]). Immediately after birth, de novo sphingolipid synthesis is also elevated in epidermal cells to supply specialized sphingolipids in support of skin barrier formation ([@bib25]). The lack of negative feedback control on sphingolipid biosynthesis caused by the absence of ORMDLs in the *Ormdl* triple KO mice may have disrupted these or other critical developmental processes in which sphingolipids play an essential role.

Our results indicate that the individual ORMDLs can partially compensate for each other in both the control of sphingolipid levels and to prevent expression of severe phenotypes. Redundancy of ORMDL function may not be surprising given the extremely high sequence identity between the three ORMDL isoforms. The reason for redundancy of ORMDLs may reflect an organismal advantage in having robust control over a pathway that generates toxic metabolites but is also required under certain developmental scenarios to produce extremely high levels of specialized sphingolipid end-products. Under circumstances of high metabolic flux, small perturbations in downstream enzyme activities or transport mechanisms could result in catastrophic consequences if ceramide levels were allowed to increase. The existence of multiple isoforms may also reflect independent functions for the ORMDLs, such as differential responses to individual ceramide species according to their chain length, degree of saturation, or some other aspect of structure. Interestingly, in *Ormdl1/3* double KO brain, dihydroceramides with very long chain fatty acids (C22-26) did not increase, whereas in Ormdl1/3 double KO sciatic nerve, dihydroceramides with very long chain fatty acids were highly elevated. This result suggests that differences exist between these tissues, either in the flux of sphingolipid substrate through the pathway or in regulation by ORMDLs.

Our results emphasize the critical role that sphingolipid synthesis plays in the nervous system, as well as the balancing act that occurs within the sphingolipid biosynthesis pathway between the production of essential sphingolipids and the control of toxic metabolic intermediates. It is well known that genetic blocks in the sphingolipid metabolic pathway, especially in lysosomal degradation, cause severe neurodegeneration ([@bib13]). We have now shown that tight regulatory control of sphingolipid synthesis via the ORMDLs is also necessary to prevent nervous system damage during myelination, which relies on a large pool of mature sphingolipids.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\            Designation                         Source or reference         Identifiers                                                                                    Additional\
  (species) or\                                                                                                                                                                           information
  resource                                                                                                                                                                                
  ------------------------ ----------------------------------- --------------------------- ---------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------
  Genetic reagent\         *Ormdl1* KO mice                    This paper                  RRID:\                                                                                         See \'Materials and methods\'
  (*M. musculus*)                                                                          IMSR_JAX:034646                                                                                

  Genetic reagent\         *Ormdl2* KO mice                    This paper                  RRID:\                                                                                         See \'Materials and methods\'
  (*M. musculus*)                                                                          IMSR_JAX:034645                                                                                

  Genetic reagent\         *Ormdl3* Floxed mice                This paper                  RRID:\                                                                                         See \'Materials and methods\'
  (*M. musculus*)                                                                          IMSR_JAX:034644                                                                                

  Genetic reagent\         *EIIA-Cre* mice                     Jackson Laboratory          RRID:[IMSR_JAX:003724](https://scicrunch.org/resolver/IMSR_JAX:003724)                         Mice expressing Cre transgene under the control *EIIa* promoter
  (*M. musculus*)                                                                                                                                                                         

  Genetic reagent\         STOP-fSPT transgenic mice           This paper                                                                                                                 See \'Materials and methods\'
  (*M. musculus*)                                                                                                                                                                         

  Genetic reagent\         *PLP/creER^T^* mice                 Jackson Laboratory          RRID:[IMSR_JAX:005975](https://scicrunch.org/resolver/IMSR_JAX:005975)                         Mice expressing tamoxifen inducible-mouse *Plp1* promoter
  (*M. musculus*)                                                                                                                                                                         

  Genetic reagent\         *Mx-Cre* mice                       Jackson Laboratory          RRID:[IMSR_JAX:003556](https://scicrunch.org/resolver/IMSR_JAX:003556)                         Mice expressing Cre transgene under the control of the mouse *Mx1* promoter
  (*M. musculus*)                                                                                                                                                                         

  Antibody                 Monoclonal anti-human SPTLC1        Santa Cruz Bio-technology   RRID:[AB_10917035](https://scicrunch.org/resolver/AB_10917035); clone H-1, cat. \# sc-374143   For western blot (1:1000 dilution)

  Antibody                 Anti-mouse IgG-HRP conjugated       Millipore                   RRID:[AB_9045](https://scicrunch.org/resolver/AB_9045); Cat. \# AP-124P                        For western blot (1:1000 dilution)

  Antibody                 Anti-mouse β-actin-HRP conjugated   Abcam                       RRID:[AB_8674](https://scicrunch.org/resolver/AB_8674); AC-15, cat \# ab49900                  For western blot (1:100,000 dilution)

  Sequence-based reagent   Ormdl1For                                                       PCR primer                                                                                     Genotyping *Ormdl1* KO mice: 5′-TGTAATGAACAGCCGTGGTAT

  Sequence-based reagent   Ormdl1Rev                                                       PCR primer                                                                                     Genotyping *Ormdl1* KO mice: 5′-GCAGAAGGGGATGCTGAGTAATA

  Sequence-based reagent   Ormdl2For                                                       PCR primer                                                                                     Genotyping *Ormdl2* KO mice: 5′-CACATGCAGCAGTCCTACCA

  Sequence-based reagent   Ormdl2Rev                                                       PCR primer                                                                                     Genotyping *Ormdl2* KO mice: 5′-GTTGGACTCCTGCCTGATCC

  Sequence-based reagent   NDEL1                                                           PCR primer                                                                                     Genotyping *Ormdl3* KO mice: 5′-GCAGGAGGAAGAGGCCCTCAG

  Sequence-based reagent   NDEL2                                                           PCR primer                                                                                     Genotyping *Ormdl3* KO mice: 5′-CTCTTGACTGCCGCTCTGCAAAAGAG

  Sequence-based reagent   SIAE4                                                           PCR primer                                                                                     Genotyping *Ormdl3* KO mice: 5′-CACGGCGCAGGGTTCTAATACATAC

  Sequence-based reagent   ForSPT                                                          PCR primer                                                                                     Genotyping fSPT mice: 5′-CATCGAGCTGAAGGGCATCG

  Sequence-based reagent   RevSPT                                                          PCR primer                                                                                     Genotyping fSPT mice: 5′-GTTATCTAGAATTATAGACGCGCTAG

  Sequence-based reagent   ForR26                                                          PCR primer                                                                                     Genotyping fSP*T* mice: 5′-AGTTCTCTGCTGCCTCCTGGCTTCT

  Sequence-based reagent   CreFor                                                          PCR primer                                                                                     Genotyping fSPT mice: 5′-GCCTGCATTACCGGTCGATGC

  Sequence-based reagent   CreRev                                                          PCR primer                                                                                     Genotyping: 5′-CAGGGTGTTATAAGCAATCCC

  Sequence-based reagent   TaqmanFWD                                                       *Ormdl1* taqman assay primer                                                                   *Ormdl1* taqman assay primer: 5′-ATGAATGTTGGAGTTGCCCAC

  Sequence-based reagent   TaqmanREV                                                       *Ormdl1* taqman assay primer                                                                   *Ormdl1* taqman assay primer: 5′-GAACACTGCAGAAGGGGATG

  Sequence-based reagent   *Ormdl1* probe                      Applied Biosystems          Custom                                                                                         *Ormdl1* taqman assay probe: 5′-TGTAGATGACCCAAAATGGT

  Sequence-based reagent   *Ormdl2* assay-on-demand            Applied Biosystems          Mm00452481_g1                                                                                  

  Sequence-based reagent   *Ormdl3* assay-on-demand            Applied\                    Mm00787910_sH                                                                                  
                                                               Biosystems                                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mouse generation and genotyping {#s4-1}
-------------------------------

To obtain *Ormdl1* and *Ormdl2* KO alleles ([Figure 1B and C](#fig1){ref-type="fig"}), sgRNAs (Horizon, Cambridge, UK) corresponding to sequences in exon 2 downstream of the start codon of each gene, and the Cas9 protein (Horizon) were microinjected into C57BL/6 (Taconic Biosciences, Rensselaer, NY) embryos. The injected embryos were implanted into pseudo-pregnant surrogates ([@bib36]). The offspring were screened by sequencing to identify mice carrying insertions or deletions in either the *Ormdl1* or the *Ormdl2* gene. For *Ormdl1*, the following primers were used to amplify the region edited by the corresponding sgRNA/Cas9 complex: 5′-GGCTAGAAAAACAAGCTTTGGAA-3′; 5′-TGGTGTCTCACTGCTTCCTTC-3′. The *Ormdl1* PCR fragment was sequenced using 5′-CAAGCTTTGGAAAAAGAAGCCA-3′ as a primer. For *Ormdl2*, the following primers were used to amplify the region edited by the sgRNA/Cas9: 5′-GAACAGCTGGTGACTTTGTTTTGT-3′; 5′-GAGTAAAAACCCCACTTGTGTGAG-3′. The *Ormdl2* PCR fragment was sequenced using 5′-TGTTTTGTTTTGGTTGGGATAG-3′ as a primer. Founder mice with the deletions shown in [Figure 1B and C](#fig1){ref-type="fig"} were backcrossed to C57BL/6 mice to derive mouse colonies carrying the *Ormdl1* and *Ormdl2* KO alleles.

To modify the *Ormdl3* locus, a targeting vector was prepared using a 10.2-kb genomic region containing exons 2 to 4 ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The linearized targeting vector was transfected into BA1 (C57BL/6 × 129/SvEv) embryonic stem cells (Ingenious Targeting Laboratory, Ronkonkoma, NY). Correctly targeted embryonic stem cells were identified by PCR and Southern blotting. The neomycin cassette was removed by crossing F~1~ mice to mice expressing FRT recombinase (Stock No: 009086, Jackson Laboratory, Bar Harbor, ME). *Ormdl3* KO mice were obtained by subsequent crossing with C57BL/6 mice expressing Cre recombinase under the EIIA promoter (Stock No: 003724, Jackson Laboratory) ([@bib27]) to excise the DNA between the LoxP sites, causing the deletion of the entire amino-acid-coding sequence for *Ormdl3* ([Figure 1D](#fig1){ref-type="fig"}). Mice were then backcrossed seven times to C57BL/6 mice to derive the *Ormdl3* mouse colonies.

To generate mice that enabled the conditional expression of fusion SPT (fSPT), the three individual SPT subunits (in the following order: SPTLC2, SPTSSA, and SPTLC1) were cloned as a single-chain coding unit ([@bib2]; [@bib15]) linked to EGFP by a T2A peptide sequence ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). A stop cassette flanked by LoxP sites was inserted between the CAG promoter and the fSPT coding unit ([@bib30]). The expression cassette was inserted into the *Rosa26* locus using the TARGATT methodology ([@bib35]). fSPT transgenic mice were crossed with mice expressing Cre recombinase under the control of a tamoxifen-inducible-mouse *Plp1* promoter (Stock No: 005975, Jackson Laboratory) ([@bib12]) or a pIpC-inducible *Mx1* promoter (Stock No: 003556, Jackson Laboratory) ([@bib26]). fSPT*/iPlp1-Cre* mice were fed a tamoxifen diet (500 mg/kg, Envigo, Somerset, NJ) starting at 4 weeks of age to induce Cre-mediated excision of the stop cassette. fSPT*/Mx1-Cre* mice were injected intraperitonally 3 times every other day starting at 8 weeks of age with 150 μL of 2.5 mg/mL pIpC (Sigma, St. Louis, MO) in PBS to induce Cre-mediated removal of the stop cassette. fSPT/*Mx1-Cre* mice were analyzed 4 weeks after starting pIpC treatment. fSPT*/iPlp1-Cre* mice were analyzed for 2 weeks after treatment with tamoxifen diet.

Mice were genotyped by PCR of tail-snip DNA using the following primers and reactions:

*Ormdl1* KO: Ormdl1For 5′-TGTAATGAACAGCCGTGGTAT-3′; Ormdl1Rev 5′-GCAGAAGGGGATGCTGAGTAATA-3′. PCR conditions: denaturation, 94°C for 10 min; amplification, 94°C for 20 s, 60°C for 30 s, 72°C for 40 s; and extension, 72°C for 7 min (35 cycles). The expected product size for the WT allele is 85 bp and for the targeted allele is 72 bp.

*Ormdl2* KO: Ormdl2For 5′-CACATGCAGCAGTCCTACCA-3′; Ormdl2Rev 5′-GTTGGACTCCTGCCTGATCC-3′. PCR conditions: denaturation, 94°C for 5 min; amplification, 94°C for 20 s, 60°C for 30 s, 72°C for 40 s; and extension, 72°C for 7 min (35 cycles). The expected product size for the WT allele is 139 bp and for the targeted allele is 112 bp.

*Ormdl3* KO: NDEL1 5′-GCAGGAGGAAGAGGCCCTCAG-3′, NDEL2 5′-CTCTTGACTGCCGCTCTGCAAAAGAG-3′, SIAE4 5′-CACGGCGCAGGGTTCTAATACATAC-3′. PCR conditions: denaturation, 94°C for 5 min; amplification, 94°C for 20 s, 60°C for 30 s, 72°C for 75 s; and extension, 72°C for 7 min (35 cycles). The expected product size for the WT allele is 362 bp and for the targeted allele is 487 bp.

fSPT allele: ForSPT 5′-CATCGAGCTGAAGGGCATCG-3′; RevSPT 5′-GTTATCTAGAATTATAGACGCGCTAG-3′. PCR conditions: denaturation, 94°C for 5 min; amplification, 94°C for 1 min, 60°C for 1 min, 72°C for 1 min; and extension, 72°C for 7 min (35 cycles). The expected product size for the fSPT allele is 386 bp.

WT allele: ForR26 5′-AGTTCTCTGCTGCCTCCTGGCTTCT-3′; RevR26 5′-CATAAACCCCAGAGACTCCTATCCTC-3′. PCR conditions: denaturation, 94°C for 5 min; amplification, 94°C for 1 min, 61°C for 1 min, 72°C for 1 min; and extension, 72°C for 7 min (35 cycles). The expected product size for the WT allele is 287 bp.

*Plp1-Cre* and *Mx1-Cre*: CreFor 5′-GCCTGCATTACCGGTCGATGC-3′; CreRev 5′-CAGGGTGTTATAAGCAATCCC-3′. PCR conditions: denaturation, 94°C for 5 min; amplification, 94°C for 1 min, 60°C for 1 min, 72°C for 1 min; and extension, 72°C for 7 min (35 cycles). The expected product size for the *Cre* allele is 500 bp.

All animal procedures were approved by the National Institute of Diabetes and Digestive and Kidney Diseases Animal Care and Use Committee and were performed in accordance with National Institutes of Health guidelines.

Gene expression {#s4-2}
---------------

Total RNA from brain was purified using TRIzol (Applied Biosystems, ThermoFisher Scientific, Waltham, MA) according to the manufacturer's recommendations. cDNA was synthesized using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). mRNA levels were determined by RT-qPCR using predesigned Assay-on-Demand probes and primers (Applied Biosystems) for *Ormdl2* (Mm00452481_g1) and *Ormdl3* (Mm00787910_sH). For *Ormdl1*, custom primers and probes were designed to detect the *Ormdl1* allele: taqmanFWD 5′-ATGAATGTTGGAGTTGCCCAC-3', taqmanREV 5′-GAACACTGCAGAAGGGGATG-3′, *Ormdl1* Probe: 5′-TGTAGATGACCCAAAATGGT-3′ (Applied Biosystems). Probes were selected to correspond to sequences that were deleted in the *Ormdl* gene-altered mice. Reactions were run on a QuantStudio 3 (Applied Biosystems).

Wire-hang behavioral test {#s4-3}
-------------------------

To evaluate strength and coordination, we performed the forelimb wire hang test ([@bib1]). Mice were allowed to hang with their forelimbs from an elevated wire placed above a cage. The latency time to when the mouse fell was recorded, for a maximum of 180 s.

Electron microscopy {#s4-4}
-------------------

Transmission EM analysis was performed on sciatic nerves as previously described ([@bib3]).

Lipid analysis {#s4-5}
--------------

Dihydrosphingosine, sphingosine and individual fatty-acid species of ceramide, dihydroceramide and hexosylceramide (glucosylceramide and galactosylceramide) were measured by HPLC-tandem MS by the Lipidomics Core at the Medical University of South Carolina on a Thermo Finnigan (Waltham, MA) TSQ 7000 triple quadrupole mass spectrometer, operating in a multiple reaction monitoring-positive ionization mode as previously described ([@bib5]). Sphingolipid concentration was normalized using protein concentration determined by the BCA assay (Pierce, ThermoFisher Scientific). Total ceramide and dihydroceramide levels were determined by summing the individual fatty-acid species.

Western blot {#s4-6}
------------

Expression of the fSPT transgene was detected in total tissue lysates. Sciatic nerves were harvested and homogenized in RIPA buffer (ThermoFisher Scientific) supplemented with protease inhibitor cocktail (ThermoFisher Scientific) and phosphatase inhibitor cocktail (Roche Life Science, Indianapolis, IN). Liver was harvested and homogenized in Cell Lysis Buffer (Cat\#9803 s, Cell Signaling Technology, Danvers, MA) with protease inhibitors (Crystalgen, Commack, NY). Samples were incubated 30 min on ice and later spun at 14,000 x *g* at 4°C for 10 min. Proteins were resolved on a 4--12% Bis-Tris gel (ThermoFisher Scientific), then transferred to nitrocellulose membranes (ThermoFisher Scientific). The membranes were blocked in 5% non-fat dry milk, 0.05% Tween-20 in TBS, then probed with the indicated antibodies. fSPT expression was detected using monoclonal anti-human SPTLC1 (clone H-1, sc-374143, 1:1000 dilution) (Santa Cruz Biotechnology, Dallas, TX), followed by anti-mouse IgG, HRP-conjugated (AP-124P, Millipore, Burlington, MA). Membranes were reprobed with anti-mouse β-actin (monoclonal AC-15, HRP-conjugated) (Abcam, Cambridge, MA) to provide a loading control. Signal was detected by chemiluminescence (ECL Prime Western Blotting Detection Reagents, GE Healthcare Bio-Sciences, Pittsburgh, PA) visualized with an Amersham Imager 680 blot and gel imager (GE Healthcare Bio-Sciences).

SPT activity {#s4-7}
------------

SPT enzymatic activities were measured by acyl-CoA dependent incorporation of \[^3^H\] serine into sphingoid bases as previously described ([@bib22]). Each assay was performed using liver microsomes (200 μg protein) with 50 μM palmitoyl-CoA.

Statistical analysis {#s4-8}
--------------------

Sample sizes were estimated on the basis of our previous publications ([@bib3]; [@bib2]; [@bib5]; [@bib34]). Statistical analysis was performed using unpaired Student's *t* test, one-way analysis of variance (ANOVA) with Bonferroni's multiple comparison test, or Chi-square analysis, as described in the legends, using Prism software (GraphPad, San Diego, CA). P-values \<0.05 were considered statistically significant.

Data availability {#s4-9}
-----------------

All data generated during this study are included in the manuscript and supporting files. Source data files have been provided.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Sphingolipids play critical roles in many cellular signaling pathways -- they form the myelin membrane that insulates neuronal axons and their bioactive metabolites such as ceramide regulate cell growth. Because of their importance and the potential toxicity of metabolic intermediates, sphingolipid levels are carefully regulated by feedback inhibition of its synthesis, a process mediated by the Ormdl family of proteins. The three members of this family sense elevated ceramide levels and inhibit a key enzyme in the sphingolipid biosynthesis pathway to ultimately lower sphingolipid levels. Still, the functional importance of Ormdls in physiological settings remains unclear. Here, Clarke et al. address this comprehensively by generating knockout mice for each of the three Ormdl genes, for combinations of two of the three genes, and for all three genes. Knockout of all three Ormdls is embryonic-lethal, emphasizing the essential nature of this regulation. Moreover, they find that the Ormdls function in an isoform-specific manner to maintain control of sphingolipid biosynthesis in a specific physiological context -- myelination -- where there is a high demand for these lipids. In the absence of proper Ormdl-mediated regulation, they find elevated levels of sphingolipids and toxic intermediates, which lead to severe myelination defects and neurological abnormalities. These studies bring a deeper understanding of the role of the Ormdl family of proteins in the tight regulation of sphingolipid biosynthesis, an essential feature of all cells, but particularly in tissues such as in the brain, skin, and testes, where high levels of sphingolipid synthesis occur.

**Decision letter after peer review:**

Thank you for submitting your article \"The Ormdl genes regulate the sphingolipid synthesis pathway to ensure proper myelination and neurologic function in mice\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Huda Zoghbi as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Brian Wattenberg (Reviewer \#1); Gerhild van Echten-Deckert (Reviewer \#2); Roger Sandhoff (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This article is an important contribution to the sphingolipid and myelination fields. It presents the first description of the combined deletion of all three ORMDL proteins in mice, which leads to impaired myelination and hence severe neurological problems. ORMDL proteins are the major regulators of sphingolipid synthesis and this paper provides us with an excellent model to study the regulation and function of this important lipid class. All three reviewers were highly enthusiastic about the study and judged it to be of significant interest to scientists working on lipid homeostasis and neuronal function. Like all pioneering studies, there are a few issues raised from the data that are listed below. Addressing these points with data that the authors may already have or by discussion could further enhance the clarity and impact of this study.

Essential revisions:

1\) Given the increased amounts of ceramide in the myelin of ORMDL1,3 double knockouts, it would be interesting to know the amount of GalCer and of sulfatide in these samples. This data would enhance the paper, but is not strictly required.

2\) The latest study on ORMDLs by Davis et al., 2019, showed that in addition to ceramide, sphingosine could also exert a significant inhibitory effect of ORMDLs on SPT. Further, it has been suggested that in neurons lacking S1P-lyase, the excess of free and phosphorylated sphingoid bases is responsible for ORMDL1,3 inhibition of SPT. No changes in ceramide amounts were detected in those neurons. Thus, Figure 1A might be misleading suggesting that ceramide is the only culprit. This point could be briefly addressed in the text.

3\) In the discussion of Morbust Charcot-Marie-Tooth (CMT), please include a reference to Atkinson et al., 2017, which shows that S1P-lyase, a catabolic enzyme of sphingolipid metabolism is also involved in CMT.

4\) The authors find no upregulation of (dihydro)ceramides with very long chain fatty acids (C22-26) in the brain of ORMDL1 and 3-DKO (Figure 1---figure supplement 2), whereas in this DKO the highest upregulation of (dihydro)ceramides in the sciatic nerve is found exactly with those containing very long chain fatty acids (Figure 3---figure supplement 1). As the major phenotype described affects the sciatic nerve, it may be worth picking up this result with one or two sentences in the Discussion. Especially the downstream products of ceramides in myelin-producing cells, the cerebrosides and sulfatides are very rich in very long chain fatty acids. Might there be a difference in this downstream flux between oligodendrocytes of the brain and Schwann cells of the sciatic nerve?

5\) In the global knockouts, it is not clear if the effects on myelination are on the myelinating cells or, for example, on glial or neuronal cells. This is approached in the manuscript by the experiments with oligodendrocyte/Schwann cell-specific overexpression of SPT. The authors note that effects could be on reduced viability of the myelinating cells, but do not measure that directly. The major sphingolipids in myelin are cerebrosides and sulfatides, and to a lesser extent sphingomyelin. If available, it would be interesting to know the levels of those lipids, which would directly impact on the observation of redundant myelin.

6\) Table 1 first line, second to last column states: *Ormdl1^-/-^ Ormdl2^-/-^ Ormdl^+/+^*. However, shouldn\'t it be *Ormdl1^-/-^ Ormdl2^-/-^ Ormdl^+/-^*?

7\) Legend of Figure 1 should contain a link to the supplemental showing which (dihydro)ceramide species underlie the levels presented here.

8\) Legend of Figure 4---figure supplement 1, Figure 1---figure supplement 2, Figure 3---figure supplement 1, and figure 4---figure supplement 2 should contain short information as to the length of the sphingoid base analyzed to reveal the levels of sphingoid bases and ceramides (most likely it was the major one with 18 carbons).
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Author response

> Essential revisions:
>
> 1\) Given the increased amounts of ceramide in the myelin of ORMDL1,3 double knockouts, it would be interesting to know the amount of GalCer and of sulfatide in these samples. This data would enhance the paper, but is not strictly required.

Thank you for this excellent suggestion. We have now included levels of hexosylceramide, comprising both glucosyl and galactosylceramide, in sciatic nerves from *Ormdl1* single KO, *Ormdl3* single KO, *Ormdl1/3* double KO and WT mice (Figure 3E). Hexosylceramide levels in the *Ormdl1* and *Ormdl3* single KO sciatic nerves were increased by about 20-50% compared to WT. In sciatic nerves from *Ormdl1/3* double KO mice, hexosylceramide levels were lower by about 50% compared to WT, even though they contained 14 times dihydroceramide and the amount 8 times the amount of ceramide of the WT (Figure 3E).

These results are in line with the concept outlined in the Discussion (second paragraph) in which ORMDLs are necessary to restrain SPT activity to insure that the amounts of precursor sphingolipids produced do not exceed the capacity of the pathway to generate mature sphingolipids (hexosylceramides). Accordingly, in the absence of both ORMDL 1 and 3, the amounts of precursor ceramide produced greatly exceed the capacity the terminal steps of the pathway to convert it to mature hexosylceramide. The buildup of excessively high sphingolipid precursor levels in the *Ormdl* 1/3 double KO sciatic nerve may cause cellular damage resulting in the loss of myelinated axons, and, thus, the reduced hexosylceramide levels.

> 2\) The latest study on ORMDLs by Davis et al., 2019, showed that in addition to ceramide, sphingosine could also exert a significant inhibitory effect of ORMDLs on SPT. Further, it has been suggested that in neurons lacking S1P-lyase, the excess of free and phosphorylated sphingoid bases is responsible for ORMDL1,3 inhibition of SPT. No changes in ceramide amounts were detected in those neurons. Thus, Figure 1A might be misleading suggesting that ceramide is the only culprit. This point could be briefly addressed in the text.

The possible involvement of free and phosphorylated sphingoid bases in the ORMDL-mediated SPT regulation is now included in the Discussion (first paragraph).

> 3\) In the discussion of Morbust Charcot-Marie-Tooth (CMT), please include a reference to Atkinson et al., 2017, which shows that S1P-lyase, a catabolic enzyme of sphingolipid metabolism is also involved in CMT.

We have included this interesting point and reference in the Discussion (third paragraph).

> 4\) The authors find no upregulation of (dihydro)ceramides with very long chain fatty acids (C22-26) in the brain of ORMDL1 and 3-DKO (Figure 1---figure supplement 2), whereas in this DKO the highest upregulation of (dihydro)ceramides in the sciatic nerve is found exactly with those containing very long chain fatty acids (Figure 3---figure supplement 1). As the major phenotype described affects the sciatic nerve, it may be worth picking up this result with one or two sentences in the Discussion. Especially the downstream products of ceramides in myelin-producing cells, the cerebrosides and sulfatides are very rich in very long chain fatty acids. Might there be a difference in this downstream flux between oligodendrocytes of the brain and Schwann cells of the sciatic nerve?

We have now addressed this point in the Discussion (fifth paragraph).

> 5\) In the global knockouts, it is not clear if the effects on myelination are on the myelinating cells or, for example, on glial or neuronal cells. This is approached in the manuscript by the experiments with oligodendrocyte/Schwann cell-specific overexpression of SPT. The authors note that effects could be on reduced viability of the myelinating cells, but do not measure that directly. The major sphingolipids in myelin are cerebrosides and sulfatides, and to a lesser extent sphingomyelin. If available, it would be interesting to know the levels of those lipids, which would directly impact on the observation of redundant myelin.

This is a good point. As discussed in the response to comment 1, we have now included measurements of hexosylceramide levels of sciatic nerves from *Ormdl1* single KO, *Ormdl3* single KO, *Ormdl1/3* double KO and WT mice (Figure 3E).

We have also included the hexosylceramide levels for sciatic nerve with oligodendrocyte/Schwann cell-specific overexpression of SPT (Figure 4G). Similar to the *Ormdl*1/3 double KO mice, we find levels amount of lower levels hexosylceramide but extremely high levels of dihydroceramide and ceramide compared with WT. The reduced levels of hexosylceramide can be attributed to loss of myelinated axons.

The abnormally high ceramide level relative to the hexosylceramide level suggests that abnormal myelin lipid composition due to excessive, unbalanced sphingolipid synthesis may be a cause of redundant myelination, as outlined in the Discussion.

> 6\) Table 1 first line, second to last column states: Ormdl1^-/-^ Ormdl2^-/-^ Ormdl^+/+^. However, shouldn\'t it be Ormdl1^-/-^ Ormdl2^-/-^ Ormdl^+/-^?

Thank you for pointing this out. The top row of Table 1 has been corrected and the data has been updated.

> 7\) Legend of Figure 1 should contain a link to the supplemental showing which (dihydro)ceramide species underlie the levels presented here.

Supplementary figures have now been included as figure supplements in all cases.

> 8\) Legend of Figure 4---figure supplement 1, Figure 1---figure supplement 2, Figure 3---figure supplement 1, and Figure 4---figure supplement 2 should contain short information as to the length of the sphingoid base analyzed to reveal the levels of sphingoid bases and ceramides (most likely it was the major one with 18 carbons).

The length of the sphingoid base in all the determinations was C18. This information has been added to the legends of Figure 1---figure supplement 2, Figure 3---figure supplement 1, Figure 4---figure supplement 1, Figure 4---figure supplement 2.

[^1]: These authors contributed equally to this work.
